/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

MAXCYTE INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.548 -0.0318(-3.18%) MXCT at 04 Dec 2025 04:39 PM Medical Devices
Lowest Today 1.45
Highest Today 1.585
Today’s Open 1.45
Prev. Close 1.57
52 Week High 5.20
52 Week Low 1.26
Day’s Range: Low 1.45 High 1.585
52-Week Range: Low 1.26 High 5.20
1 day return -
1 Week return -13.71
1 month return -6.79
3 month return +11.02
6 month return -36.55
1 year return -58.79
3 year return -72.19
5 year return -
10 year return -

Institutional Holdings

BlackRock Inc 9.57

Cadian Capital Management LP 8.36

Morgan Stanley - Brokerage Accounts 6.59

Mirabella Financial Services LLP 6.19

Vanguard Group Inc 5.25

Vitruvian Partners 4.73

Mudita Advisors LLP 3.16

RGI UK Listed Smaller Coms B Acc 3.10

Vanguard Total Stock Mkt Idx Inv 2.58

Unicorn AIM VCT Ord 2.33

Geode Capital Management, LLC 2.33

iShares Russell 2000 ETF 2.31

AXA Framlington Health Fund - R Income 2.07

AXA SA 2.07

State Street Corp 2.05

FMR Inc 1.82

Dimensional Fund Advisors, Inc. 1.64

Chevy Chase Trust Holdings, Inc. 1.62

IFSL Marlborough UK Micro Cap Gr A Acc 1.14

Vanguard Institutional Extnd Mkt Idx Tr 1.10

Silvercrest Asset Management Group LLC 1.01

Citadel Advisors Llc 0.96

Fidelity Small Cap Index 0.96

iShares Russell 2000 Value ETF 0.86

River UK Micro Cap Ord 0.78

Northern Trust Corp 0.74

Fidelity Advisor Equity Growth I 0.71

Morgan Stanley Inception 0.69

Morgan Stanley Inst Inception I 0.69

Renaissance Technologies Corp 0.67

MI Chelverton UK Equity Growth B Acc 0.66

Royce & Associates, LP 0.62

Fidelity VIP Growth Initial 0.60

iShares Biotechnology ETF 0.54

Fidelity Extended Market Index 0.54

Royce Micro Cap Trust 0.45

Vanguard Russell 2000 ETF 0.45

EQ/Morgan Stanley Small Cap Growth K 0.44

Goldman Sachs Group Inc 0.42

Rice Hall James & Associates, LLC 0.39

Market Status

Strong Buy: 6

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 167.48 M

PB Ratio 1.0414

PE Ratio 0.0

Enterprise Value 100.18 M

Total Assets 239.47 M

Volume 1264133

Company Financials

Annual Revenue FY23:38047000 38.0M, FY22:44261500 44.3M, FY21:33894100 33.9M, FY20:26168900 26.2M, FY19:21620700 21.6M

Annual Profit FY23:33331600 33.3M, FY22:39163100 39.2M, FY21:30246700 30.2M, FY20:23401900 23.4M, FY19:19121500 19.1M

Annual Net worth FY23:-37454600 -37.5M, FY22:-19781100 -19.8M, FY21:-20126600 -20.1M, FY20:-12642000 -12.6M, FY19:-13576100 -13.6M

Quarterly Revenue Q3/2025:6829000 6.8M, Q2/2025:8507000 8.5M, Q1/2025:10390000 10.4M, Q3/2024:8164000 8.2M, Q2/2024:10429000 10.4M

Quarterly Profit Q3/2025:6313000 6.3M, Q2/2025:6988000 7.0M, Q1/2025:8893000 8.9M, Q3/2024:6236000 6.2M, Q2/2024:7907000 7.9M

Quarterly Net worth Q3/2025:-12416000 -12.4M, Q2/2025:-12357000 -12.4M, Q1/2025:-10261000 -10.3M, Q3/2024:-11557000 -11.6M, Q2/2024:-9375000 -9.4M

Fund house & investment objective

Company Information MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Organisation Medical Devices

Employees 114

Industry Medical Devices

CEO Mr. Maher Masoud

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow